Description: Freeline is a clinical-stage biotechnology company focused on AAV-based gene therapy targeting the liver. Its vision is to create better lives for people suffering from chronic, systemic diseases using the potential of gene therapy as a one-time treatment to provide a potential functional cure. Freeline is headquartered in the U.K. and has operations in Germany and the U.S.
Home Page: www.freeline.life
FRLN Technical Analysis
Stevenage Bioscience Catalyst
Stevenage,
SG1 2FX
United Kingdom
Phone:
44 14 3890 6870
Officers
| Name | Title |
|---|---|
| Mr. Michael J. Parini J.D. | CEO, COO, Pres & Exec. Director |
| Dr. Amit Chunilal Nathwani M.D., Ph.D. | Founder, Independent Clinical & Scientific Advisor and Director |
| Dr. Markus Horer Ph.D. | Founder, CTO & Managing Director GmbH |
| Mr. James Bircher | Chief Technical Operations Officer |
| Dr. Pamela Foulds M.D. | Chief Medical Officer |
| Mr. Paul M. Schneider | Chief Financial Officer |
| Dr. Henning R. Stennicke Ph.D. | Chief Scientific Officer |
| Arne Naeveke Ph.D. | VP & Head of Corp. Communications |
| Ms. Nicole Jones SPHR | Chief People Officer |
| Dr. Alison Long M.D., Ph.D. | Interim Chief Medical Officer, Sr. VP & Head of Clinical Devel. |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.559 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2020-08-07 |
| Fiscal Year End: | December |
| Full Time Employees: | 235 |